Drug Search Results
More Filters [+]

SPN-538

Alternative Names: spn-538, spn 538, spn538
Latest Update: 2024-04-24
Latest Update Note: Clinical Trial Update

Product Description

SPN-538 (Trokendi XR,Supernus Pharmaceuticals, Inc.) is a novel extended-release, once-daily capsule formulation of TPM that may improve tolerability and adherence.

Mechanisms of Action: Sodium Channel Antagonist

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Supernus
Company Location: ROCKVILLE MD 20850
Company CEO: Jack A. Khattar
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SPN-538

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Migraine Disorders|Headache Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

538P401

P4

Recruiting

Migraine Disorders|Headache Disorders

2024-12-31

Recent News Events

Date

Type

Title